StockNews.com Initiates Coverage on Pulmatrix (NASDAQ:PULM)

Analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Stock Performance

Shares of PULM stock opened at $6.22 on Wednesday. The company has a market capitalization of $22.70 million, a P/E ratio of -2.36 and a beta of 1.54. Pulmatrix has a 52 week low of $1.55 and a 52 week high of $8.44. The company’s 50 day moving average price is $3.20 and its two-hundred day moving average price is $2.45.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.